The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMVT | -21.98% | -52.75% | -13.91% | +135% |
| S&P | +12.65% | +91.73% | +13.89% | +128% |
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
The biotech looks as if it has a promising treatment for an autoimmune disorder.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.11M | -33.7% |
| Market Cap | $2.73B | -29.1% |
| Market Cap / Employee | $7.55M | 0.0% |
| Employees | 362 | 74.9% |
| Net Income | -$120.61M | -38.4% |
| EBITDA | -$127.12M | -34.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $598.91M | 6.9% |
| Accounts Receivable | $1.94M | -19.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -71.50% | -13.6% |
| Return On Invested Capital | -43.85% | 2.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$117.41M | -53.7% |
| Operating Free Cash Flow | -$117.41M | -54.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.65 | 8.08 | 7.13 | 3.85 | -38.16% |
| Price to Tangible Book Value | 7.65 | 8.08 | 7.13 | 3.85 | -38.16% |
| Enterprise Value to EBITDA | -32.02 | -28.59 | -18.78 | -16.80 | -52.01% |
| Return on Equity | -92.2% | -74.2% | -62.5% | -77.6% | 20.19% |
| Total Debt | $0.05M | $0.02M | $0.10M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
